Sartorius Stedim Biotech : 2020 guidance raised, forecasts and target price lifted, Neutral vs Buy
>2020 guidance upgraded - Ahead of its announcements on 21 July (H1 2020), Sartorius Stedim Biotech indicated yesterday evening it was now targeting sales growth of 26 to 30% for 2020 (previously 17 to 21%) and an underlying EBITDA margin of around 31% (previously 30%).Indeed, based on H1 2020 (order intake: +34.1% - sales cc: +22% - underlying EBITDA margin: 30.2%), SSB raised its forecasts, despite the COVID-19 crisis.The upward revision to forecasts is pa...Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Co.'s solutions cover fermentation, filtration, purification, fluid management and lab technologies and membrane chromatography, including various conventional lab products to biopharmaceutical laboratories. Co.'s technologies, products and services are used to develop and manufacture medications and vaccines using biological methods. Co.'s products covers all upstream and downstream steps in the production of active pharmaceutical ingredients. It specializes in single-use products and offers technical consulting and services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.